At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab (MK-3475) With and Without Bevacizumab for Recurrent Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Bevacizumab for Glioblastoma. Completed, enrolled 80 participants across 8 sites.
Detailed Summary
In this research study, the investigators are looking to determine the effectiveness of Pembrolizumab (MK-3475) when given with bevacizumab or when given alone for the treatment of recurrent glioblastoma multiforme (GBM). This study will also test the safety and tolerability of Pembrolizumab (MK-3475) when given alone or with bevacizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartFeb 2015
Primary CompletionAug 2016
Study CompletionSep 2020
TodayJul 2026
First PostedJan 13, 2015
Enrollment StartFeb 9, 2015
Primary CompletionAug 28, 2016
Study CompletionSep 14, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.5 years ago
Interventions
Pembrolizumabdrug
Bevacizumabdrug